Organon's Ba2 CFR affirmed by Moody's, outlook revised to negative

Published 10/04/2025, 15:54
© Reuters.

Investing.com -- Moody's Ratings has affirmed Organon & Co.'s Ba2 Corporate Family Rating (CFR), Ba2-PD Probability of Default Rating (PDR), Ba1 senior secured first lien bank credit facility ratings, Ba1 senior secured notes, and B1 senior unsecured notes on April 10, 2025. The speculative grade liquidity rating remains unchanged at SGL-1. However, Moody's has revised Organon's outlook to negative from stable.

The revision of the outlook to negative is due to the anticipation that Organon's leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth prospects as the company manages the recent patent expirations of its cholesterol drug Atozet, which is its second largest product by revenues.

Although growth prospects may improve over time with accelerating products like Vtama for atopic dermatitis, the overall organic growth outlook is expected to be subdued due to ongoing generic competition against its established brands. Additionally, it is expected that Organon will have limited ability to pay down debt in the next 12-18 months due to substantial one-time expenses, business development spend, and dividend payments. The negative outlook reflects uncertainty in Organon's willingness and ability to improve credit metrics while balancing financial policies with its pursuit of longer-term growth prospects.

The Ba2 Corporate Family Rating for Organon reflects its niche position in the global pharmaceutical industry, offering women's health products, biosimilars, and established off-patent products. Organon has good diversity at the product and geographic level. The established brands have good name recognition in global markets. The women's health franchise has favorable growth prospects owing to demographic trends including rising demand for fertility treatments.

However, these strengths are offset by limited organic growth due to the nature of established brands which face pricing and volume pressure amid competition from generics. Organon's free cash flow remains constrained by costs associated with restructuring activities and planned exits from supplier arrangements. Yet, free cash flow is expected to improve as these costs decline over time, which could facilitate improvement in credit ratios over time if the company chooses to pursue more moderate financial policies including debt repayment. There is an event risk of acquisitions as the company is likely to pursue initiatives to improve earnings growth.

Factors that could lead to an upgrade include improvement in organic growth rates, substantial expansion in free cash flow, and debt/EBITDA sustained below 3.5x. Conversely, factors that could lead to a downgrade include a significant contraction in revenue due to pricing pressure or competition, substantial debt-financed acquisitions, or debt/EBITDA sustained over 4.5x for a prolonged period.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.